一本大道无码,麻豆文化传媒www网站入口,噜噜国产精品,亚洲高潮性爱免费久久视频

  1. 首頁 > 標(biāo)準(zhǔn)品 > 中藥標(biāo)準(zhǔn)品 > 三萜及其苷類 > 黃芪甲苷

黃芪甲苷

    
分析標(biāo)準(zhǔn)品,HPLC≥98%

Astragaloside IV

源葉
B20564 一鍵復(fù)制產(chǎn)品信息
84687-43-4
C41H68O14
784.97
MFCD16036240
貨號(hào) 規(guī)格 價(jià)格 上海 北京 武漢 南京 購買數(shù)量
B20564-20mg 分析標(biāo)準(zhǔn)品,HPLC≥98% ￥150.00 >10 7 10 9
B20564-100mg 分析標(biāo)準(zhǔn)品,HPLC≥98% ￥450.00 >10 - - -
B20564-2.5g 分析標(biāo)準(zhǔn)品,HPLC≥98% ￥4800.00 6 - - -
產(chǎn)品介紹 參考文獻(xiàn)(115篇) 質(zhì)檢證書(COA) 摩爾濃度計(jì)算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

Astragaloside IV 是從黃芪中分離得到的一種皂苷，抑制ERK1/2和JNK激活，在乳腺癌細(xì)胞 MDA-MB-231 中，下調(diào)(MMP)-2和(MMP)-9的信號(hào)通路。

熔點(diǎn)： 295-296°C
沸點(diǎn)： 895.7 °C at 760 mmHg
比旋光度： ?+24.4°(c=0.23，甲醇)
外觀： 無色針晶
溶解性： DMSO  :  ≥  100  mg/mL  (127.39  mM)
儲(chǔ)存條件： 2-8℃
注意： 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

參考文獻(xiàn)(115篇)

110. [IF=3.4] Zhibo Hu et al."Astragaloside IV attenuates podocyte apoptosis via regulating TXNIP/NLRP3/GSDMD signaling pathway in diabetic nephropathy."Diabetology & Metabolic Syndrome.2024 Dec;16:296 109. [IF=6.7] Si-wei Wang et al."Astragaloside IV inhibits retinal pigment epithelial cell senescence and reduces IL-1β mRNA stability by targeting FTO-mediated m6A methylation."PHYTOMEDICINE.2025 Jan;:156408 108. [IF=3.1] Wenjing Liu et al."Characterization of metabolites of ganoderic acids extract from Ganoderma lucidum in rats using UHPLC–MS/MS."JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS.2025 Jun;258:116764 107. [IF=8.7] Liangyin Wei et al."Oxymatrine and astragaloside IV co-loaded liposomes: Scale-up purposes and their enhancement of anti-PD-1 efficacy against breast cancer."Materials Today Bio.2025 Mar;:101634 106. [IF=4.9] Rong Gao et al."Th1/Th2 Immune Imbalance in the Spleen of Mice Induced by Hypobaric Hypoxia Stimulation and Therapeutic Intervention of Astragaloside IV."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2025 Jan;26(6):2584 105. [IF=4.4] Wenshuang Wang et al."Kunxinning granules alleviate perimenopausal syndrome by supplementing estrogen deficiency."Frontiers in Pharmacology.2025 Mar;16: 104. [IF=1.5] Qian Xiaojing et al."Qualitative, Quantitative Analysis and Pharmacokinetic Study of Potentially Active Components of Huangxueyishen Decoction Based on UPLC-MS/MS."JOURNAL OF CHROMATOGRAPHIC SCIENCE.2025 Apr;63(4): 103. [IF=3.8] Zicong Wu et al."Astragaloside IV Treats Parkinson’s Disease by Regulating the Proliferation and Differentiation of NSCs through the SHH–Nurr1 Pathway."Stem Cells International.2024 Sep;2024(1):2792909 102. [IF=2.8] Zhu Yuanying et al."New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification."JOURNAL OF PHARMACY AND PHARMACOLOGY.2024 Aug;: 101. [IF=3.8] Li Wei et al."Quantitative comparison of bile acid glucuronides sub-metabolome between intrahepatic cholestasis and healthy pregnant women."ANALYTICAL AND BIOANALYTICAL CHEMISTRY.2024 Jul;:1-13 100. [IF=5.6] Zuyu Lu et al."Physicochemical heterogeneity and mechanical separation of the phloem and xylem in Astragalus membranaceus."INDUSTRIAL CROPS AND PRODUCTS.2024 Dec;221:119182 99. [IF=1.3] Hong-Ping Wang et al."Screening of potential α-glucosidase inhibitors from astragalus membranaceus by affinity ultrafiltration screening coupled with UPLC-ESI-Orbitrap-MS method."JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH. 98. [IF=6] Jiaheng Shan et al."β-Cyclocitral from Lavandula?angustifolia Mill. Exerts Anti-Aging Effects on Yeasts and Mammalian Cells via Telomere Protection, Antioxidative Stress, and Autophagy Activation."Antioxidants.2024 Jun;13(6):715 97. [IF=6.7] Yinhuang Gao et al."Buqi Huoxue Tongnao prescription protects against chronic cerebral hypoperfusion via regulating PI3K/AKT and LXRα/CYP7A1 signaling pathways."PHYTOMEDICINE.2024 Sep;132:155844 96. [IF=10.2] Guo Hong et al."Homologous-magnetic dual-targeted metal-organic framework to improve the Anti-hepatocellular carcinoma efficacy of PD-1 inhibitor."JOURNAL OF NANOBIOTECHNOLOGY".2024 Dec;22(1):1-20 95. [IF=2.6] Fan Yang et al."Preliminary Exploration of Potential Active Ingredients and Molecular Mechanisms of Yanggan Yishui Granules for Treating Hypertensive Nephropathy Using UPLC-Q-TOF/MS Coupled with Network Pharmacology and Molecular Docking Strategy."Journal 94. [IF=5.5] Xiangyu Chen et al."Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ischemia–reperfusion injury."CNS Neuroscience & Therapeutics".2024 Apr; 30(4): e14725 93. [IF=7.9] Yun Shan et al."The Role of Macrophage-Derived Exosomes in Reversing Peritoneal Fibrosis: Insights from Astragaloside IV."PHYTOMEDICINE".2024 Apr;:155683 92. [IF=10.8] Xiangtian Deng et al."Microenvironment-responsive smart hydrogels with antibacterial activity and immune regulation for accelerating chronic wound healing."JOURNAL OF CONTROLLED RELEASE".2024 Apr;368:518 91. [IF=5.4] Jialing Sun et al."Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology."JOURNAL OF ETHNOPHARMACOLOGY".2024 Feb;:117985 90. [IF=3.1] Yang Tao et al."Astragaloside IV modulates gut macrophages M1/M2 polarization by reshaping gut microbiota and SCFA in sepsis."SHOCK.2023 Nov;:10.1097/SHK.0000000000002262 89. [IF=5.2] Yang Ma et al."Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p/CNDP1 Axis."Cancers.2023 Jan;15(20):5048 88. [IF=5.4] Keyan Jiao et al."Glycosides of Buyang Huanwu decoction inhibits inflammation associated with cerebral ischemia-reperfusion via the PINK1/Parkin mitophagy pathway."JOURNAL OF ETHNOPHARMACOLOGY.2024 Jan;:117766 87. [IF=5.4] Wenjuan Ma et al."Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation."JOURNAL OF ETHNOPHARMACOLOGY.2024 Apr;323:117752 86. [IF=3.5] Yanyun Guan et al."Astragaloside IV inhibits epithelial-mesenchymal transition and pulmonary fibrosis via lncRNA-ATB/miR-200c/ZEB1 signaling pathway."GENE.2024 Mar;897:148040 85. [IF=17.1] Hong Guo et al."Magnetic Metal–Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma."ACS Nano.2023;XXXX(XXX):XXX-XXX 84. [IF=3.1] Xi Jie et al."Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway."BMC Pulmonary Medicine.2023 Dec;23(1):1-12 83. [IF=3.1] Yuan Zhang et al."Isolating, Identifying, and Analyzing the Biological Characteristics of Pathogens Causing Postharvest Disease in Fresh Radix?Astragali."Horticulturae.10.3390/horticulturae9091019 82. [IF=5.8] Xingru Peng et al."Novel mPEG-CS-modified flexible liposomes-reinforced thermosensitive sol-gel reversible hydrogels for ocular delivery of multiple drugs with enhanced synergism."COLLOIDS AND SURFACES B-BIOINTERFACES.10.1016/j.colsurfb.2023.113560 81. [IF=1.6] Lu Zhang et al."Astragaloside IV relieves IL-1β-induced human nucleus pulposus cells degeneration through modulating PI3K/Akt signaling pathway."MEDICINE.2023 Aug 18; 102(33): e34815 80. [IF=5.4] Huibo Dai et al."Network pharmacology, molecular docking and experimental verification of the mechanism of huangqi-jixuecao herb pair in treatment of peritoneal fibrosis."JOURNAL OF ETHNOPHARMACOLOGY.2023 Jul;:116874 79. [IF=3.1] Yanmin Wang et al."Study on the dynamic metabolic characteristic of main active ingredients in Danggui Buxue Decoction by liquid chromatography-tandem mass spectrometry based on in situ sequential metabolism strategy."JOURNAL OF SEPARATION SCIENCE.2023 Ju 78. [IF=4.6] Wei Li et al."Characterization of Metabolic Correlations of Ursodeoxycholic Acid with Other Bile Acid Species through In Vitro Sequential Metabolism and Isomer-Focused Identification."MOLECULES.2023 Jan;28(12):4801 77. [IF=5.195] Jiaxiong Yao et al."Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice."JOURNAL OF ETHNOPHARMACOLOGY.2023 Sep;313:116533 76. [IF=6.656] Chuanjing Cheng et al."Astragaloside IV targets PRDX6, inhibits the activation of RAC subunit in NADPH oxidase 2 for oxidative damage."PHYTOMEDICINE.2023 Mar;:154795 75. [IF=3.195] Yan, Fanchen et al."Glycoside combinations of Buyang Huanwu decoction ameliorate atherosclerosis via STAT3, HIF-1, and VEGF."NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY.2023 Jan;:1-17 74. [IF=5.195] Zhen Xue et al."Untargeted metabolomics reveals the combination effects and mechanisms of Huangqi-fuzi herb-pair against doxorubicin-induced cardiotoxicity."JOURNAL OF ETHNOPHARMACOLOGY.2023 Apr;305:116109 73. [IF=6.449] Yanmei Li et al."Regional variations and plant compartments shape the community structures of the endophytic microbiome and secondary metabolites of Astragalus mongholicus."INDUSTRIAL CROPS AND PRODUCTS.2023 Feb;192:116037 72. [IF=1.698] Jinyan Wu et al."Chemical Identification and Antioxidant Screening of Bufei Yishen Formula using an Offline DPPH Ultrahigh-Performance Liquid Chromatography Q-Extractive Orbitrap MS/MS."International Journal of Analytical Chemistry.2022 Oct 15;2022:142380 71. [IF=5.168] Pan Wang et al."Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay."CHEMICO-BIOLOGICAL INTERACTIONS.2022 Nov;367:110199 70. [IF=3.887] Xiang-Lin KONG et al."Effect of astragaloside IV and salvianolic acid B on antioxidant stress and vascular endothelial protection in the treatment of atherosclerosis based on metabonomics."Chinese Journal of Natural Medicines.2022 Aug;20:601 69. [IF=6.656] Xinying Fu et al."Glycosides from Buyang Huanwu Decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway."PHYTOMEDICINE.2022 Oct;105:154385 68. [IF=4.769] Xinyi Chai et al."Screening of immune cell activators from Astragali Radix using a comprehensive two-dimensional NK-92MI cell membrane chromatography/C18 column/time-of-flight mass spectrometry system."Journal of Pharmaceutical Analysis. 2022 May;: 67. [IF=4.451] Liang Wang et al."Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway."J Funct Foods. 2022 Jan;88:104905 66. [IF=3.168] Yuqiong Lin et al."Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways."Diabet Metab Synd Ob. 2022 Jan;15:131-140 65. [IF=4.432] Hua Tian et al."Astragaloside IV protects against C/EBP homologous protein-mediated apoptosis in oxidized low-density lipoprotein-treated macrophages by promoting autophagy."Eur J Pharmacol. 2022 Mar;:174912 64. [IF=1.662] Hui Shi et al."Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway."J Food Biochem. 2021 Jul;45(7):e13757 63. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950 62. [IF=3.098] Haifeng Jin et al."Astragaloside IV blocks monocrotaline?induced?pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling."Int J Mol Med. 2021 Feb;47(2):595-606 61. [IF=3.434] Du Xiaoxun et al."Tanshinone IIA and Astragaloside IV Inhibit miR-223/JAK2/STAT1 Signalling Pathway to Alleviate Lipopolysaccharide-Induced Damage in Nucleus Pulposus Cells."Dis Markers. 2021;2021:6554480 60. [IF=3.69] Jingyi Hu et al."Qingchang Huashi Formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function."J Ethnopharmacol. 2021 Feb;266:113394 59. [IF=3.69] Xiaoping Wang et al."Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats."J Ethnopharmacol. 2020 Apr;252:112536 58. [IF=3.7] Jing-Jing Yang et al."Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells."Nutr Metab Cardiovas. 2020 May;30:829 57. [IF=3.882] Kunpeng Yin et al."Lanthanide Metal–Organic Framework-Based Fluorescent Sensor Arrays to Discriminate and Quantify Ingredients of Natural Medicine."Langmuir. 2021;37(17):5321–5328 56. [IF=3.935] Yu-li Jiang et al."HPLC fingerprinting-based multivariate analysis of chemical components in Tetrastigma Hemsleyanum Diels et Gilg: Correlation to their antioxidant and neuraminidase inhibition activities."J Pharmaceut Biomed. 2021 Oct;205:114314 55. [IF=4.225] Zhang Wei et al."Five Active Components Compatibility of Astragali Radix and Angelicae Sinensis Radix Protect Hematopoietic Function Against Cyclophosphamide-Induced Injury in Mice and t-BHP–Induced Injury in HSCs."Front Pharmacol. 2019 Aug;0:936 54. [IF=4.36] Pin Gong et al."Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway."J Ethnopharmacol. 2021 Dec;281:114558 53. [IF=6.081] Tongji Liu et al."Improvement Effect of Lotus Leaf Flavonoids on Carbon Tetrachloride-Induced Liver Injury in Mice."Biomedicines. 2020 Feb;8(2):41 52. [IF=1.146] Han Gao et al."Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali."Neuroreport. 2018 May 2; 29(7): 577–582 51. [IF=3.098] Xiao Chen et al."Astragaloside IV ameliorates high glucose?induced renal tubular epithelial?mesenchymal transition by blocking mTORC1/p70S6K signaling in HK?2 cells."Int J Mol Med. 2019 Feb;43(2):709-716 50. [IF=4.213] Qiangyuan Fan et al."Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo."Int J Pharmaceut. 2018 Dec;552:360 49. [IF=4.354] Ting Liu et al."Synthetic Access Toward Cycloastragenol Glycosides."J Org Chem. 2017;82(8):4170–4178 48. [IF=4.759] Yuping Zhang et al."On-line surface plasmon resonance-high performance liquid chromatography–tandem mass spectrometry for analysis of human serum albumin binders from Radix Astragali."J Chromatogr A. 2013 Jun;1293:92 47. [IF=7.514] Yuping Zhang et al."Integration of magnetic solid phase fishing and off-line two-dimensional high-performance liquid chromatography–diode array detector–mass spectrometry for screening and identification of human serum albumin binders from Radix Astragali 46. Yang, Jing-Jing, et al. "Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells." Nutrition, Metabolism and Cardiovascular Diseases 30.5 (2020): 829-842.https://doi.org/10.1016/j.numecd.2020.01.00 45. Fan, Qiangyuan, et al. "Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: preparation by supercritical fluid technology and evaluation in vitro and in vivo."?International journal of pharmaceutics?552.1-2 (201 44. Ting Liu, Jin-Xi Liao, Yang Hu, Yuan-Hong Tu, and Jian-Song Sun The Journal of Organic Chemistry 2017 82 (8), 4170-4178 DOI: 10.1021/acs.joc.7b00080 43. Liu, Tongji, et al. "Improvement effect of lotus leaf flavonoids on carbon tetrachloride-induced liver injury in mice." Biomedicines 8.2 (2020): 41.https://doi.org/10.3390/biomedicines8020041 42. Wang, Xiaoping, et al. "Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats." Journal of ethnopharmacology 252 (2020): 112536.https://doi.org/10.1016/j.jep.2019.112536 41. 范小龍,陳冉,吳婉琴,劉國姣,黃坤,江豐.液相色譜串聯(lián)質(zhì)譜法測(cè)定食品中淫羊藿苷等20種功能成分[J].食品與機(jī)械,2021,37(01):86-93+98. 40. 田文倉. 不同生長年限及采收期子洲黃芪鑒別特征及其質(zhì)量、產(chǎn)量差異分析[D].北京中醫(yī)藥大學(xué),2020. 39. 徐芳芳,張秀莉,侯滔,曲臘臘,王紀(jì)霞,劉艷芳,梁鑫淼.天然產(chǎn)物中FFA1受體新激動(dòng)劑的發(fā)現(xiàn)與研究[J].上海中醫(yī)藥大學(xué)學(xué)報(bào),2021,35(01):12-19. [4]宮夢(mèng)琪,孫倩,李振.天麻中天麻素提取工藝優(yōu)化及抑制α-葡萄糖苷酶活性研究[J].中國果菜,2020,40(09):14-17+23. 38. 彭勝男,陶琰心,洪婷,楊海燕,黃青.黃芪甲苷通過mTORC1通路調(diào)控IgA腎病大鼠脾淋巴細(xì)胞分化[J].中國免疫學(xué)雜志,2021,37(04):421-425. 37. 張悅,于學(xué)煒,于宏川,仲偉一,楊陽.黃芪甲苷調(diào)節(jié)miR-21基因抑制腎癌細(xì)胞增殖和誘導(dǎo)細(xì)胞凋亡的機(jī)制探討[J].現(xiàn)代腫瘤醫(yī)學(xué),2020,28(18):3145-3150. 36. 曾廣偉,安慧仙,方東,高釗,賈建軍,朱舜明.黃芪甲苷抑制缺血再灌注誘導(dǎo)的大鼠心肌細(xì)胞凋亡[J].現(xiàn)代生物醫(yī)學(xué)進(jìn)展,2020,20(24):4612-4617. 35. 彭勝男,陶琰心,洪婷,楊海燕,黃青.黃芪甲苷通過mTORC1通路調(diào)控IgA腎病大鼠脾淋巴細(xì)胞分化[J].中國免疫學(xué)雜志,2021,37(04):421-425. 34. 馮美杰,李蕾,王穎航,徐兢鴻,潘志.黃芪甲苷對(duì)人類風(fēng)濕關(guān)節(jié)炎成纖維樣滑膜細(xì)胞增殖及白細(xì)胞介素6分泌的影響[J].中國中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志,2020,26(10):1484-1487. 33. 程歡,米雅慧,劉明平,于洋,黎同明.黃芪多糖、黃芪甲苷對(duì)大黃酸腸吸收的影響[J].中藥新藥與臨床藥理,2021,32(02):240-244. 32. 姚萱航,劉翠晶,常晶茹,張雪薇,劉霞.2種類型膜莢黃芪主要藥效成分含量及關(guān)鍵酶基因表達(dá)量差異研究[J].中草藥,2021,52(07):2072-2081. 31. 馮紫薇. 子洲黃芪飲片質(zhì)量等級(jí)標(biāo)準(zhǔn)研究[D].北京中醫(yī)藥大學(xué),2020. 30. 趙宏月,張東偉,龐琳琳,張歡,于睿.黃芪甲苷及人參皂苷Rg1對(duì)高脂大鼠心肌缺血再灌注損傷后心肌細(xì)胞凋亡的影響[J].遼寧中醫(yī)雜志,2021,48(02):188-191. 29. 孫樂,吳鵬,王春艷,張學(xué)蘭,金玉翠,劉海濱.黃芪飲片炮制工藝優(yōu)選[J].時(shí)珍國醫(yī)國藥,2020,31(07):1616-1619. 28. 張素清,陳冰,陳思邈,董靜怡,陳偉燕,張宇燕.R語言與正交試驗(yàn)分析處理優(yōu)化黃芪中黃芪甲苷提取工藝的比較[J].中國中醫(yī)急癥,2020,29(08):1420-1423. 27. 支旭然 劉洪濤 吳茵 等. UPLC-MS/MS法同時(shí)測(cè)定腎康注射液中7個(gè)有效成分[J]. 藥物分析雜志 2017 037(001):37-42. 26. 燕玉奎, 郭玫, 邵晶,等. 紅芪及其不同提取部位中主要活性成分的含量測(cè)定[J]. 中獸醫(yī)醫(yī)藥雜志, 2020, v.39;No.220(01):22-25. 25. 張婕,梁程程,楊愛仲,齊聰.增免抑瘤方及有效組分對(duì)卵巢癌干細(xì)胞裸鼠移植瘤Notch/Jagged1信號(hào)通路的影響[J].中國實(shí)驗(yàn)方劑學(xué)雜志,2020,26(15):46-53. 24. 鄒龍, 李歡歡, 劉輝,等. 補(bǔ)陽還五湯總苷膠囊的制備工藝優(yōu)選. 中國實(shí)驗(yàn)方劑學(xué)雜志. 23. 鄒龍 劉輝 李仲秋 等. HPLC測(cè)定補(bǔ)陽還五湯總苷中黃芪甲苷和芍藥苷的含量[J]. 湖南中醫(yī)藥大學(xué)學(xué)報(bào) 2012 32(005):39-42. 22. 李富欣, 于蓓蓓, 劉瑾,等. 茯黃顆粒的質(zhì)量標(biāo)準(zhǔn)研究[J]. 西部中醫(yī)藥, 2019, 032(002):P.44-48. 21. 何昊 許暢 王興中 蘇力 張家旭. 四種不同方法提取黃芪中黃芪甲苷的對(duì)比研究[J]. 化工科技(3期):25-28. 20. 韋赫, 程林, 吳培,等. 黃芪皂苷生物合成對(duì)短期水分變化的響應(yīng)[J]. 中國中藥雜志, 2019, 44(03):39-45. 19. 李楊, 郭超, 張小平,等. 黃芪皂苷-氫氧化鋁佐劑復(fù)合物對(duì)bFGF腫瘤疫苗抗乳腺癌活性的影響[J]. 河西學(xué)院學(xué)報(bào), 2018, 34(05):32-37. 18. 成鵬,白銀亮,胡彩莉,連佛彥,周海宇.黃芪甲苷通過調(diào)控FoxO3a/Wnt2/β-catenin通路抑制去卵巢大鼠骨質(zhì)疏松的作用[J].中國實(shí)驗(yàn)方劑學(xué)雜志,2018,24(15):161-166. 17. 張悅,于學(xué)煒,于宏川,仲偉一,楊陽.黃芪甲苷調(diào)節(jié)miR-21基因抑制腎癌細(xì)胞增殖和誘導(dǎo)細(xì)胞凋亡的機(jī)制探討[J].現(xiàn)代腫瘤醫(yī)學(xué),2020,28(18):3145-3150. 16. 張怡, 靳曉飛, 周曉紅,等. 黃芪甲苷調(diào)控自噬抑制缺氧缺糖/復(fù)氧復(fù)糖HT22細(xì)胞凋亡[J]. 中國藥理學(xué)通報(bào), 2019, 035(004):519-524. 15. 俞曼殊, 史俊, 趙君誼,等. 黃芪甲苷調(diào)控Akt信號(hào)通路阻抑人腹膜間皮細(xì)胞間充質(zhì)轉(zhuǎn)化的實(shí)驗(yàn)研究[J]. 南京中醫(yī)藥大學(xué)學(xué)報(bào), 2019, 35(01):53-57. 14. 劉晨旭,張玫,楊洋,魏鵬翔,魏群利.黃芪甲苷對(duì)高糖誘導(dǎo)下大鼠腎小球系膜細(xì)胞TGF-β1/Smad信號(hào)通路的影響[J].徐州醫(yī)科大學(xué)學(xué)報(bào),2019,39(09):641-643. 13. 賈力維, 沃曉嫚, 王謙博,等. 黃芪甲苷對(duì)非小細(xì)胞肺癌A549細(xì)胞增殖及凋亡相關(guān)蛋白表達(dá)的影響[J]. 黑龍江大學(xué)自然科學(xué)學(xué)報(bào), 2019, 036(001):84-89. 12. 熊莉,呂夢(mèng)娟,竇德宇,馬玉紅.黃芪甲苷對(duì)血管緊張素Ⅱ誘導(dǎo)腎小球系膜細(xì)胞增殖及炎癥因子表達(dá)的影響[J].中國應(yīng)用生理學(xué)雜志,2018,34(05):414-417+421. 11. 趙彩萍,劉翠玲,梁爽,李欣蓉,柳雪蕾,朱美玲.黃芪甲苷對(duì)脂多糖誘導(dǎo)人胃黏膜上皮細(xì)胞GES-1的抗炎作用及機(jī)制研究[J].中藥新藥與臨床藥理,2020,31(08):918-923. 10. 張吉, 臧東鈺. 黃芪甲苷對(duì)急性肺損傷大鼠內(nèi)質(zhì)網(wǎng)應(yīng)激介導(dǎo)影響[J]. 中國民族民間醫(yī)藥, 2014, 000(015):19-20. 9. 武建毅, 沈清, 金赟潔,等. 黃芪甲苷對(duì)BALB/C小鼠肝癌H22腹水瘤抑制作用及機(jī)制[J]. 中國藥物警戒, 2016, 13(003):138-142. 8. 朱易平, 李茹柳, 時(shí)玉霞,等. 黃芪總皂苷對(duì)IEC-6細(xì)胞增殖及相關(guān)蛋白表達(dá)的影響[J]. 中藥新藥與臨床藥理, 2019, 30(01):60-65. 7. 倪琳, 魏學(xué)冰, 陳德道,等. 黃芪烏梅降糖顆粒的制備工藝與質(zhì)量分析[J]. 海峽藥學(xué), 2020, v.32;No.240(01):10-15. 6. 李玉美, 陳新梅, 徐溢明,等. 納秒脈沖電場(chǎng)滅菌對(duì)舒心糖漿質(zhì)量影響的初步研究[J]. 化工時(shí)刊, 2015(04):31-32+52. 5. 孟琦, 寶麗, 張燁,等. 基于腸道菌群調(diào)節(jié)的小檗堿和黃芪甲苷聯(lián)用降糖機(jī)制研究[J]. 食品與藥品, 2020(3):169-175. 4. 孫銘憶, 李冰韶, 王永潔,等. 基于模糊層次分析法優(yōu)選復(fù)方黃芪水浸膏提取工藝路線[J]. 中草藥, 2018. 3. 陳開, 周靜, 李敏,等. 基于大孔樹脂的黃芪中黃芪甲苷提取液純化工藝研究[J]. 中國中醫(yī)急癥, 2017, 26(011):1881-1883. 2. 袁一凡 陳曉月 劉保霞 劉笑 李瑞宏 祁金龍 賈慶忠.UPLC-MS/MS法同時(shí)測(cè)定康艾注射液中11種成分[J].中草藥 2017 48(13):2660-2665. 1. 張素清 陳冰 陳思邈 等. R語言與正交試驗(yàn)分析處理優(yōu)化黃芪中黃芪甲苷提取工藝的比較[J]. 中國中醫(yī)急癥 2020(8).

質(zhì)檢證書(COA)

如何獲取質(zhì)檢證書(COA)?
請(qǐng)輸入貨號(hào)和一個(gè)與之匹配的批號(hào)。
例如:
批號(hào)：JS298415 貨號(hào)：S20001-25g
在貨品標(biāo)簽上如何找到貨號(hào)和批號(hào)?

摩爾濃度計(jì)算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關(guān)產(chǎn)品